These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 225329)

  • 1. Comparative monkey neurovirulence of Sabin type III poliovirus vaccines.
    Boulger LR; Marsden SA; Magrath DI; Taffs LF; Schild GC
    J Biol Stand; 1979 Apr; 7(2):97-111. PubMed ID: 225329
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurovirulence testing of oral poliovaccine in the rhesus monkey.
    Arya SC
    Indian J Pathol Microbiol; 1976 Jul; 19(3):185-94. PubMed ID: 186408
    [No Abstract]   [Full Text] [Related]  

  • 3. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
    Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
    Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The behaviour of Sabin attenuated poliovirus strains in the central nervous system of rhesus monkeys.
    Arya SC
    J Biol Stand; 1977; 5(4):275-81. PubMed ID: 200628
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurovirulence of polioviruses isolated from sewage and stool of healthy children. I. Studies on neurovirulence, antigenic marker and RCT-40 mrker of type 2 strains.
    Wilterdink JB; Smit GL; Verlinde JD
    Arch Gesamte Virusforsch; 1969; 28(1):68-76. PubMed ID: 4315814
    [No Abstract]   [Full Text] [Related]  

  • 6. Monkey neurovirulence of live, attenuated (Sabin) type I and type II poliovirus vaccines.
    Marsden SA; Boulger LR; Magrath DI; Reeve P; Schild GC; Taffs LF
    J Biol Stand; 1980; 8(4):303-9. PubMed ID: 7009616
    [No Abstract]   [Full Text] [Related]  

  • 7. The assessment of OPV vaccines by the monkey neurovirulence test: why and how to qualify the experts in histology of central nervous system.
    Poirier B; Morgeaux S; Fuchs F
    Vaccine; 2002 Nov; 21(1-2):115-9. PubMed ID: 12443669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible influence of measles virus infection of cynomolgus monkeys on the outcome of the neurovirulence test for oral poliovirus vaccine.
    Contreras G; Furesz J
    Biologicals; 1992 Mar; 20(1):27-33. PubMed ID: 1319180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
    Kohara M; Abe S; Yoshioka I; Nomoto A
    Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of type 3 poliovirus variants with increased L-cystine-dependence as live vaccines.
    Elbert LB; Chumakov MP; Krutyanskaya GL; Ralph NM; Tyufanov AV; Sokolova IS; Alpatova GA
    Arch Gesamte Virusforsch; 1971; 33(3):259-70. PubMed ID: 4329636
    [No Abstract]   [Full Text] [Related]  

  • 11. Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence.
    Horie H; Koike S; Kurata T; Sato-Yoshida Y; Ise I; Ota Y; Abe S; Hioki K; Kato H; Taya C
    J Virol; 1994 Feb; 68(2):681-8. PubMed ID: 8289371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preliminary studies on the neurovirulence of poliomyelitis vaccine (oral) prepared in vero cells.
    Guo R; Chen SF; Luo GX; Luo QS; Xu QF
    Proc Chin Acad Med Sci Peking Union Med Coll; 1988; 3(2):104-7. PubMed ID: 2848237
    [No Abstract]   [Full Text] [Related]  

  • 13. An infectious cDNA clone of the poliovirus Sabin strain could be used as a stable repository and inoculum for the oral polio live vaccine.
    Kohara M; Abe S; Kuge S; Semler BL; Komatsu T; Arita M; Itoh H; Nomoto A
    Virology; 1986 May; 151(1):21-30. PubMed ID: 3008430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of a mathematical model for neurovirulence assay of attenuated poliovirus.
    Arya SC
    J Biol Stand; 1977; 5(4):283-7. PubMed ID: 200629
    [No Abstract]   [Full Text] [Related]  

  • 15. The potential use of viral genomic markers in estimating the neurovirulence of oral poliomyelitis vaccine (OPV): regulatory aspects.
    Fenyves A
    Dev Biol Stand; 1993; 78():157-9. PubMed ID: 8388826
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature-sensitive viruses derived from the Sabin type 3 virus.
    Abe S; Ota Y; Doi Y; Nomoto A; Nomura T; Chumakov KM; Hashizume S
    Virology; 1995 Jun; 210(1):160-6. PubMed ID: 7793068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of serial passage on Sabin oral poliomyelitis vaccine virus in secondary monkey kidney versus Vero cells as measured by the monkey neurovirulence test.
    Dommann CJ
    J Med Primatol; 1994 Sep; 23(7):388-92. PubMed ID: 7731028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience in Canada with the new revised monkey neurovirulence test for oral poliovirus vaccine.
    Contreras G; Furesz J; Karpinski K; Grinwich K; Gardell C
    J Biol Stand; 1988 Jul; 16(3):195-205. PubMed ID: 2844825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ON THE NEUROVIRULENCE TEST OF LIVE POLIOVIRUS VACCINES. I. BASES, TECHNIC AND EVALUATION OF THE RESEARCH ON NEUROVIRULENCE MEASUREMENT IN MONKEYS].
    BONIN O; UNTERHARNSCHEIDT F
    Arch Psychiatr Nervenkr; 1964 Nov; 206():260-71. PubMed ID: 14344120
    [No Abstract]   [Full Text] [Related]  

  • 20. TgPVR21 mice for testing type-3 oral poliovirus vaccines: role of clinical observation and histological examination.
    Dragunsky E; Chernokhvostova Y; Taffs R; Chumakov K; Gardner D; Asher D; Nomura T; Hioki K; Levenbook I
    Vaccine; 1997 Dec; 15(17-18):1863-6. PubMed ID: 9413095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.